HOOK250117C2500
- 0.10
- 0.000.00%
HOOKIPA Pharma Newsroom
HOOKIPA Pharma Inc. (NASDAQ:HOOK) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough
RBC Downgrades Hookipa, Slashes Price Target
Express News | HOOKIPA Pharma Inc : RBC Cuts to Sector Perform From Outperform; Cuts Target Price to $2 From $48
Hookipa Pharma Price Target Lowered to $7 From $24 at JMP Securities
Hookipa Pharma Announces Workforce Reduction of 80%, Pause of Eseba-vec Program
Sector Update: Health Care Stocks Climb Thursday Afternoon
HOOKIPA Pharma to Cut Workforce by 80%, Shift Focus to KRAS Cancer Program
JMP Securities Maintains HOOKIPA Pharma(HOOK.US) With Buy Rating, Cuts Target Price to $7
Strategic Shift and Partnership Potential Drive Buy Rating for HOOKIPA Pharma
Express News | HOOKIPA Pharma Inc: Will Focus Primarily on Progressing the Phase 1-Ready Hb-700 Program for the Treatment of Kras Mutant Cancers
Express News | HOOKIPA Pharma - Early Termination of Hpv16+ Trial Not Due to Efficacy or Safety
Express News | HOOKIPA Pharma - to Pause Clinical Development in Eseba-Vec Program
Express News | HOOKIPA Pharma - Restructuring Plan to Begin in Q4 2024, Complete by H1 2025
Express News | HOOKIPA Pharma Inc - on November 18, Co Approved a Planto Reduce Workforce by Approximately 80%
Analysts Are Bullish on These Healthcare Stocks: Hookipa Pharma (HOOK), Cue Biopharma (CUE)
Companies Like HOOKIPA Pharma (NASDAQ:HOOK) Could Be Quite Risky
HOOKIPA Pharma Is Maintained at Outperform by RBC Capital
HOOKIPA Pharma Analyst Ratings
HOOKIPA Pharma GAAP EPS of -$1.10 Beats by $0.18, Revenue of $4.7M Misses by $0.25M
Express News | HOOKIPA Pharma Inc : RBC Cuts Target Price to $48 From $50